IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor.

globenewswire.com - 2026-07-13 16:05:00

Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.

marketbeat.com - 2026-07-11 10:02:19

Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.

benzinga.com - 2026-07-09 13:01:16

Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript

seekingalpha.com - 2026-07-09 02:12:27

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care

globenewswire.com - 2026-07-08 16:05:00

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

zacks.com - 2026-07-08 13:01:12

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com - 2026-07-03 06:06:03

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

globenewswire.com - 2026-05-28 16:30:00

Tarsus Pharmaceuticals (TARS) is reiterated as a Strong Buy, with a 12-month price target of $95 per share amid sector-wide healthcare weakness. Xdemvy's Q1 sales more than doubled YoY, but unchanged 2026 revenue guidance ($670–$700M) disappointed, implying 18% annualized growth from the current quarterly run-rate. TARS is building a robust distribution moat, with nearly half of targeted ECPs prescribing Xdemvy weekly and direct-to-consumer activation up 40% QoQ.

seekingalpha.com - 2026-05-15 10:43:54

IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live in and around the eyelashes. Cena's story reflects the experience of millions who live with symptoms for years before seeking care and receiving a proper diagnosis.

globenewswire.com - 2026-05-14 08:30:00

Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 21:20:44

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

globenewswire.com - 2026-05-07 17:00:00

Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 21:41:16

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.64 per share a year ago.

zacks.com - 2026-05-06 19:31:04

Generated first quarter XDEMVY ® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027 Management to host conference call today, May 6, 2026 , at 1:30 p.m. PT / 4:30 p.m.

globenewswire.com - 2026-05-06 16:05:00

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m.

globenewswire.com - 2026-04-29 16:30:00

Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 34,442 shares of the company's stock, valued at approximately $2,820,000. Calamos Advisors LLC owned approximately 0.08% of Tarsus

defenseworld.net - 2026-04-27 04:56:59